Combination therapy for men with advanced prostate cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests combining an immunotherapy (Sipuleucel-T) with high-dose testosterone to see if it works better for men with castration-resistant prostate cancer that has spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that has spread to other parts of your body and is no longer responding to hormone therapy.
- You have not had more than two prior treatments targeting the androgen receptor (like abiraterone or enzalutamide).
- You have not had chemotherapy for your current cancer stage, unless it was given for earlier stage and progression occurred more than 12 months later.
- You have not received Sipuleucel-T or high-dose testosterone before.
- Your PSA level is 20 ng/dL or lower, and you are not using strong narcotics for cancer pain.
- You are in generally good health (able to perform daily activities) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a short course of high-dose testosterone followed by a radioactive drug (PSMA-617) can help men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to make cancer cells more sensitive to the radiation.
This study tests a combination of two drugs for men with advanced prostate cancer that has stopped responding to hormone therapy. The drugs are cabozantinib (a pill that may slow cancer growth) and a radioactive therapy that targets prostate cancer cells (177Lu-PSMA-617). The goal is to see if this combination is safe and effective.
This trial tests a new type of immune cell therapy (gamma delta T cells) targeted at a marker on prostate cancer cells to see if it can shrink bone metastases in advanced, castration-resistant prostate cancer. It’s for men who have already tried chemotherapy and newer hormone therapies and whose cancer is getting worse.
This trial tests a new combination of two treatments for prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if combining an immune-boosting drug with a vaccine can help the body fight the cancer more effectively.
This trial tests a combination of two treatments for advanced prostate cancer that has stopped responding to hormone therapy. One treatment is a targeted radiation therapy (177Lu-PSMA-617) and the other is an immunotherapy (sipuleucel-T) that helps your immune system fight the cancer.
This trial tests whether adding one extra infusion of sipuleucel-T (the same drug as Provenge) after the standard three doses can help men with advanced prostate cancer that no longer responds to hormone therapy. It is for men who have already finished their three Provenge infusions and have mild or no symptoms.
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.